BRAF and neoplasm: Regorafenib is an oral multi-target kinase inhibitor, which inhibits tumorigenesis, tumor angiogenesis and tumor microenvironment by targeting VEGFR1/2/3, TIE-2, BRAF, KIT, RET, PDGFR and FGFR (4).